BTMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BTMD is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is trading near 2.22 with only a marginal move on the day, technicals are mixed, recent financials weakened, and analyst targets have been cut. Insider buying is a positive sign, but without a clear breakout, strong growth, or a favorable proprietary trading signal, the better call is to hold rather than buy aggressively now.
BTMD shows a neutral-to-slightly constructive short-term setup but not a decisive buy signal. The MACD histogram is positive at 0.0263, yet it is contracting, which suggests momentum is fading. RSI_6 at 67.37 is near overbought territory but still marked neutral in the provided data. Moving averages are converging, indicating price compression and a lack of strong trend direction. Price closed at 2.223, just above the pivot of 2.239 and between support at 2.171 and resistance at 2.308. This suggests the stock is range-bound and not offering a clear entry confirmation.
Insiders are buying, and the buying amount increased 221.99% over the last month, which is a meaningful confidence signal. The next earnings date is 2026-05-06 after hours, which could serve as a near-term catalyst if the company beats expectations or provides a better outlook. Analyst ratings are still mixed to positive overall, with multiple Buy ratings remaining in place despite target cuts.
The company’s latest quarter in 2025/Q4 showed weaker fundamentals: revenue fell 6.87% YoY, net income dropped 47.23% YoY, EPS fell 50%, and gross margin declined to 68.03%. News flow has been quiet with no recent positive developments, hedge funds are neutral, and there is no AI Stock Picker or SwingMax signal today.
In 2025/Q4, Biote’s financial performance weakened versus last year. Revenue declined to $46.41M, down 6.87% YoY. Net income fell to $1.95M, down 47.23% YoY. EPS dropped to $0.05, down 50.00% YoY. Gross margin also compressed to 68.03%, down 4.59% YoY. These trends point to slower growth and weaker profitability in the latest reported quarter.
Analyst sentiment is mixed but leaning cautiously positive. Truist lowered its price target to $4 from $5 while keeping a Buy rating. B. Riley cut its target to $2 from $3 and kept Neutral, reflecting concern about clinic acquisition pace and attrition. Roth Capital reduced its target to $3 from $4.50 but kept Buy, while TD Cowen lowered to $2.50 from $3 and kept Buy. Overall, the Street still has some Buy ratings, but the repeated target cuts show reduced confidence and a more cautious outlook.
